Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-11-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物科技（上海）股份有限公司提名委员会议事规则（2023年11月修订）
Governance Information Classification · 95% confidence The document is titled '提名委员会议事规则' which translates to 'Nomination Committee Meeting Rules' for the company 益方生物科技（上海）股份有限公司. It details the structure, responsibilities, composition, and procedures of the Nomination Committee, which is a governance body within the company. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content focuses on governance practices, committee roles, and internal rules. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is under 5,000 characters, but it is not an announcement of a report publication; it is the actual governance document itself. Therefore, the appropriate classification is CGR with high confidence.
2023-11-22 Chinese
益方生物科技（上海）股份有限公司关联交易管理制度（2023年11月修订）
Governance Information Classification · 95% confidence The document is titled "关联交易管理制度" which translates to "Related Party Transaction Management System". It is a detailed internal policy document outlining the principles, definitions, decision-making authority, pricing principles, approval procedures, and disclosure requirements for related party transactions within the company. It references relevant laws, regulations, and stock exchange rules, and includes governance and procedural details. There is no indication that this is an announcement or summary of a report, nor does it contain financial statements or audit results. It is not a report of financial results, nor a regulatory filing or announcement. Instead, it is a governance-related document detailing internal rules and procedures for managing related party transactions. Therefore, the most appropriate classification is Governance Information (CGR).
2023-11-22 Chinese
益方生物科技（上海）股份有限公司独立董事工作制度（2023年11月修订）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, qualifications, rights, and obligations of independent directors at the company. It references company governance, legal compliance, and board structure but does not contain financial data, earnings, or audit information. It is a governance-related document outlining internal rules and practices for board members. There is no indication that this is an announcement or a report publication notice; it is a substantive governance policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2023-11-22 Chinese
益方生物关于修订《公司章程》及部分公司治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement from a company about revisions to its Articles of Association (公司章程) and several corporate governance systems. It details specific changes to governance rules, board structure, independent director qualifications, and decision-making procedures. The document is a formal announcement of these governance changes and states that the revisions will be submitted to the shareholders' meeting for approval. It also references compliance with regulatory rules and the need for registration with market supervision authorities. There are no financial statements, audit opinions, earnings data, or other financial report content. The document is not a full annual or interim report, nor is it a call transcript or legal proceeding update. It is clearly focused on governance structure and rules, making it a Governance Information filing. The document length is substantial, indicating it is the actual governance report content, not just an announcement of publication. Therefore, the appropriate classification is Governance Information (CGR).
2023-11-22 Chinese
益方生物关于召开2023年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2023 third extraordinary general meeting of shareholders for a company, including the meeting date, voting methods, agenda items, and instructions for shareholders. It includes information about election of board members and supervisors, voting procedures, and proxy forms. There is no financial data, earnings information, or report content. The document is a formal announcement of a shareholders meeting and related materials, not the meeting materials themselves or voting results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is over 6000 characters and contains detailed meeting information, supporting a high confidence classification as AGM-R.
2023-11-22 Chinese
益方生物关于董事会、监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the re-election of the company's board of directors and supervisory board members. It details the nomination and election process, candidate qualifications, and related procedural information. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and supervisory structure, which aligns with announcements about board or management changes. Therefore, the document fits the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2023-11-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.